Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
August 20, 2020: Update on Economic Observations: COVID-19 Recovery, the Road Ahead
AVBCC COVID-19 Webcast Series Replays
,
COVID-19
Featuring:
Murray Aitken, MBA
Executive Director
IQVIA Institute
Bruce S. Pyenson, FSA, MAAA
Principal & Consulting Actuary, Milliman, Inc
New York, NY
Burt Zweigenhaft, PhD, D.Litt
Editor-in-Chief,
VBCC
;
Executive Vice President, FFF Enterprises;
Executive Director and Co-Founder, Association for Value-Based Cancer Care
Although several of the financial indicators in oncology have recovered to pre-pandemic levels following dramatic declines that occurred earlier in the year, there are still significant challenges ahead. How will providers manage the backlog? What will happen to patients’ insurance coverage? How will oncology practices survive and thrive in a post–COVID-19 world?
Related Articles
mRNA COVID-19 Vaccine Appears Safe and Effective in Patients with Cancer Receiving Active Treatment
By
Chase Doyle
COVID-19
February 2022, Vol 13, No 1 Online Only
Read Article
Current and Future Effects of the COVID-19 Pandemic on Cancer Care
By
Phoebe Starr
COVID-19
June 2021, Vol 12, No 3
Read Article
Later Diagnoses, Worse Outcomes in Patients with Lung Cancer During COVID-19 May Last
By
Walter Alexander
COVID-19
,
Lung Cancer
April 2021, Vol 12, No 2
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma